Y-mAbs' SADA Platform: A Promising Approach to NHL Treatment

Y-mAbs Therapeutics, Inc. (YMAB) recently presented preclinical data and trial-in-progress posters for its Self-Assembling Dis-Assembling (SADA) platform at the 2024 American Society of Hematology (ASH) Annual Meeting. The SADA platform, specifically CD38-SADA, shows potential in treating Non-Hodgkin Lymphoma (NHL) through a novel pre-targeted radioimmunotherapy (PRIT) approach. This article explores the implications of these findings for investors and the broader market.

The SADA platform's CD38-SADA bispecific fusion protein targets CD38, a tumor-specific antigen overexpressed in various lymphoid malignancies. In preclinical studies, CD38-SADA demonstrated rapid and dose-dependent anti-tumor efficacy when used with Lutetium 177 (Lu177)-DOTA in a two-step PRIT approach. These results support the clinical development of CD38-SADA PRIT in patients with CD38-positive lymphoid malignancies.



Y-mAbs is currently conducting a Phase 1 trial (Trial 1201) to evaluate the safety and tolerability of CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL. The trial is designed to establish the optimal safe dose of CD38-SADA protein, the administration interval between CD38-SADA and Lu177-DOTA, and the Lu177-DOTA dose for tumor imaging. If successful, this trial could pave the way for CD38-SADA PRIT as a new treatment option for NHL patients.



The potential market size for NHL treatments is significant, with an estimated 74,680 new cases in the US alone in 2021. The rapid tumor response observed in preclinical studies and the ongoing Phase 1 trial position CD38-SADA PRIT as a promising competitor in the NHL therapy landscape. Positive trial results could attract more patients and healthcare providers, strengthening Y-mAbs' market position.

However, the success of CD38-SADA PRIT depends on various factors, including the safety and efficacy data from the Phase 1 trial, regulatory approval, and market acceptance. Investors should monitor the trial's progress and Y-mAbs' communications for updates on the platform's potential and market impact.

In conclusion, Y-mAbs' SADA platform, specifically CD38-SADA PRIT, shows promise in treating NHL through a novel pre-targeted radioimmunotherapy approach. The preclinical data and ongoing Phase 1 trial support the platform's potential, which could expand the addressable market for Y-mAbs and strengthen its competitive position in the NHL therapy landscape. As the trial progresses, investors should closely follow the developments to assess the platform's market impact and investment potential.